GlassScriptPhysician profile
Logan Milad Haak
NPI 1952565491
$7,468.99
in general payments reported to CMS, 2019-2025
44 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $1,046 · 2021: $1,643 · 2022: $755 · 2023: $2,028 · 2024: $570 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950 · Consulting Fee: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.09 |
| Consulting Fee | $1,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,601.05 | 2020-2025 | Dovato, Cabenuva, Rukobia |
| Regeneron Pharmaceuticals, INC. | $1,375.00 | 2023 | Eylea |
| Glaxosmithkline, LLC. | $537.87 | 2020-2024 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $447.71 | 2019-2025 | Eylea Hd |
| Emd Serono, INC. | $296.98 | 2020-2023 | Serostim |
| Theratechnologies INC. | $293.05 | 2019-2023 | Trogarzo, Egrifta |
| Novartis Pharmaceuticals Corporation | $289.88 | 2019-2022 | |
| Abbvie INC. | $241.29 | 2022-2025 | |
| Amarin Pharma, INC. | $240.98 | 2020-2022 | |
| Astellas Pharma US INC | $212.16 | 2024-2025 | Izervay |
| Genentech USA, INC. | $205.53 | 2019-2025 | Vabysmo |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2019 | |
| Apellis Pharmaceuticals, INC. | $120.72 | 2025 | Syfovre |
| Alcon Vision LLC | $119.83 | 2019 | |
| Portola Pharmaceuticals, LLC | $118.44 | 2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Haak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.